COMP <GO>
CAH vs ABBV // NET PROFIT MARGIN
Cardinal Health Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CAH 4
— ABBV 11
▲ NET PROFIT MARGIN LEADER: ABBV
LAST: $250.48 (-0.24%) • MKT CAP: $58.14B
net-margins
0.70%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.70% | 70.20% | -66.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.70% | 29.00% | +0.70 | CAH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | 33.3x | -8.80 | CAH | /valuation <GO> |
| Free Cash Flow Yield | 3.18% | 3.47% | -0.29 | ABBV | /fcf-yield <GO> |
| Operating Margin | 1.00% | 24.60% | -23.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 0.70% | 6.90% | -6.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -1.90% | 8.60% | -10.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.85% | 2.27% | -1.42 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 5.33 | -0.17 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.40% | -0.80 | CAH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 72.8 | -14.33 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 1.15 | -0.25 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.6x | 113.1x | -78.50 | CAH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $58.14B | $513.86B | -$455.72B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAH REV | ABBV REV | CAH GROSS % | ABBV GROSS % | CAH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $222.58B | $61.16B | 3.7% | 70.2% | $1.85B | $17.82B |
| FY 2024 | $226.83B | $56.33B | 3.3% | 70.0% | $3.25B | $17.83B |
| FY 2023 | $204.98B | $54.32B | 44.0% | 44.0% | -$6.38B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAH // BETA 0.90
ABBV // BETA 1.15